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Abstract
Background: Immunomodulatory drugs (IMiDs), such as lenalidomide, are therapeutically active compounds that
bind and modulate the E3 ubiquitin ligase substrate recruiter cereblon, thereby affect steady-state levels of cereblon
and cereblon binding partners, such as ikaros and aiolos, and induce many cellular responses, including cytotoxicity
to multiple myeloma (MM) cells. Nevertheless, it takes many days for MM cells to die after IMiD induced depletion
of ikaros and aiolos and thus we searched for other cereblon binding partners that participate in IMiD cytotoxicity.
Methods: Cereblon binding partners were identified from a MM cell line expressing histidine-tagged cereblon by
pulling down cereblon and its binding partners and verified by co-immunoprecipitation. IMiD effects were determined
by western blot analysis, cell viability assay, microRNA array and apoptosis analysis.
Results: We identified argonaute 2 (AGO2) as a cereblon binding partner and found that the steady-state levels of
AGO2 were regulated by cereblon. Upon treatment of IMiD-sensitive MM cells with lenalidomide, the steady-state
levels of cereblon were significantly increased, whereas levels of AGO2 were significantly decreased. It has been
reported that AGO2 plays a pivotal role in microRNA maturation and function. Interestingly, upon treatment of MM
cells with lenalidomide, the steady-state levels of microRNAs were significantly altered. In addition, silencing of AGO2 in
MM cells, regardless of sensitivity to IMiDs, significantly decreased the levels of AGO2 and microRNAs and massively
induced cell death.
Conclusion: These results support the notion that the cereblon binding partner AGO2 plays an important role in
regulating MM cell growth and survival and AGO2 could be considered as a novel drug target for overcoming IMiD
resistance in MM cells.
Keywords: Multiple myeloma (MM), Immunomodulatory drug (IMiD), Lenalidomide, Cereblon (CRBN), Argonaute 2
(AGO2), MicroRNA (miRNA)
Background
Immunomodulatory drugs (IMiDs), such as lenalido-
mide, are therapeutically active compounds widely
used in the treatment of multiple myeloma (MM) [1].
Treatment with IMiDs results in significant effects
on: immunomodulatory activities; anti-angiogenic ac-
tivities; anti-inflammatory activities; anti-proliferation;
pro-apoptotic effects; cell-cycle arrest; and inhibition
of cell migration and metastasis [2]. Although signifi-
cant remissions in patients with MM have been in-
duced with IMiDs, the molecular mechanism of
IMiDs’ action has only recently unraveled.
Using immobilized thalidomide, Ito et al. identified
cereblon (CRBN) and DNA damage-binding protein 1
(DDB1) as binding proteins and further demonstrated
that CRBN was the primary target of thalidomide-
induced teratogenicity [3]. We subsequently found that
CRBN expression was required for the anti-MM activity
of IMiDs [4].
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CRBN has been found to be an E3 ubiquitin ligase
substrate recruiter [5–7], but the full functional role of
CRBN in this complex is still not well known. In fact
CRBN also binds to BKCa [8, 9], ClC-2 [10], AMPK [11],
PSMB4 [12], ikaros (IKZF1) and aiolos (IKZF3) [13–15]
and MEIS2 [16], thus it is possible that CRBN might
function as a substrate-recruiter to bind each of these
proteins for ubiquitination by the E3 ubiquitin ligase
machinery and other binding partners with clinically
relevant function may also exist.
Indeed, in this report, we have identified argonaute 2
(AGO2), also termed eukaryotic translation initiation
factor 2 subunit C2 (EIF2C2), as a CRBN-downstream
binding factor. AGO2 plays a pivotal role in microRNA
(miRNA) maturation, stability and function [17–19]. We
show that the treatment of IMiD-sensitive MM cells
with lenalidomide significantly increased CRBN, subse-
quently decreasing both AGO2 protein and its target
miRNAs and inducing apoptosis. Furthermore, directly
reducing cellular AGO2 levels produced cellular cytotox-
icity regardless of whether they are IMiD-sensitive or
-resistant MM cells. Therefore, the expression of CRBN-
downstream binding protein AGO2, by regulating
miRNA levels, plays an important role for MM cell
growth and survival.
Results
Lenalidomide-induced cell-death is a slow process
We have found that CRBN expression is required for the
anti-MM activity of lenalidomide [4]. IKZF1 and IKZF3
were found to be CRBN-downstream binding proteins
[13–15, 20]. We have, however, noticed that although
IKZF1 and IKZF3 were degraded within hours of the
treatment with lenalidomide [13–15, 20], it can take
many days for the IMiD-sensitive MM cells to die. In
order to better understand the response of MM cells to
IMiD, lentiviral particle harboring human CRBN cDNA
infected My5 cells (My5.CRBN.His) and lentivirus vector
(as a control) infected My5 cells (My5.LV) were treated
with various concentrations of lenalidomide for several
days and the survival of the cells was monitored by
3–(4,5-dimethylthiazol-2-yl)–2,5-diphenyltetrazolium
bromide dye (MTT) assay. The results in Additional file 1:
Figure S1 indicated that My5.LV cells, which express lower
levels of CRBN, were resistant to lenalidomide,
whereas My5. CRBN. His cells, which express higher
levels of CRBN, were sensitive to lenalidomide, indi-
cating that high level of CRBN is required for the
anti-MM activity of lenalidomide. Despite the sensi-
tivity observed, high concentrations of lenalidomide
are also required for the IMiD-induced cell death
(Additional file 1: Figure S1). Even with high concen-
tration of lenalidomide, the CRBN-low MM cells,
such as My5.LV and MM1.S. Res cells (Fig. 1a and b),
cannot be efficiently killed (Fig. 1c). This observation
is consistent with the conclusion made in [21]. Of
note, the treatment of the MM cells expressing higher
levels of CRBN, such as My5. CRBN, JJN3 and
MM1.S (Fig. 1a and b), with 10 μM lenalidomide for
one day did not have significant effect on them
(Fig. 1c), suggesting that although IMiD-induced deg-
radation of IKZF1 and IKZF3 occurs within hours,
the effects of the degradation of these transcription
factors on the proteins associated with cell growth
and death may take days. These results also suggested
that there might be other un-identified CRBN down-
stream binding factors that contribute to the delayed
IMiD-induced cell death.
Identification of AGO2 as a potential CRBN-downstream
binding protein
In order to identify potential CRBN downstream
binding factors, the two MM cell lines mentioned in
Fig. 1, i.e., My5.LV and My5. CRBN. His, were used
to do the pull-down experiments with nickel-charged
agarose beads. As shown in Fig. 1, the infection of
My5 cells with lentivirus vector did not alter the sen-
sitivity to lenalidomide, whereas expression of the
His-tagged CRBN in My5 cells increased the sensitiv-
ity to IMiD, suggesting that His-tagged CRBN is func-
tional. Since we have functional His-tagged CRBN in
human MM cells, it is possible for us to pull down
the His-tagged CRBN and its binding proteins with
nickel-charged agarose beads. In addition, lentivirus
vector infected My5 (My5.LV) cells do not express
His-tagged CRBN, providing a good negative control
for our pull-down experiment.
In order to preserve their natural association be-
tween CRBN and its downstream binding proteins,
My5. CRBN. His cells and their control My5.LV cells
were broken by nitrogen cavitation without any deter-
gent. 115 proteins, including CRBN itself, cullin-4B
(CUL-4B) and AGO2, were detected in the pull-down
samples from My5.CRBN.His cell lysates, but not
from the control My5.LV cell lysates (Table 1 and
Additional file 2: Table S2). In addition, 59 proteins
with higher assigned spectra (higher than 5 fold), in-
cluding DDB1 and CUL-4A, were detected in
My5.CRBN.His cell lysates versus the negative control
My5.LV cell lysates (Table 1 and Additional file 2:
Table S2). Since CUL-4A, CUL-4B and DDB1 are
members of the E3-CRBN ubiquitin ligase complex,
pulling down each of these components with His-
tagged CRBN suggested that the other proteins, such
as AGO2 (Table 1), pulled-down from My5.CRBN.His
cells, but not from negative control cells, might also
be CRBN binding factors.
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Validation of AGO2 as a CRBN-downstream binding
protein
In order to validate AGO2 is a CRBN binding protein,
AGO2 and CRBN were expressed alone or in combin-
ation in baby hamster kidney (BHK) cells. The results in
Additional file 1: Figure S2 indicated that all the metho-
trexate (MTX) resistant BHK cells express high levels of
GFP, suggesting that the MTX resistant cells harbored
both pCDH.GFP.AGO2.42.4 and pNUT.CRBN.His plas-
mid DNAs. The results in Fig. 2a indicate that: 1)
pCDH.CRBN cells express CRBN, but not AGO2; 2)
AGO2.pNUT cells express AGO2, but not CRBN; 3)
AGO2.CRBN cells express both CRBN and AGO2.
Interestingly, the level of AGO2 in AGO2.pNUT cells
is significantly higher than in CRBN expressing
AGO2.CRBN cells (Fig. 2a), suggesting that the steady-
state levels of AGO2 might be regulated by CRBN.
To further confirm whether AGO2 is a CRBN-
downstream binding protein, cell lysates were prepared
from the aforementioned three BHK cell lines and used
to do co-immunoprecipitation (Co-IP) with our mouse
monoclonal antibody 42.4 [22] which recognizes the
epitope tag in AGO2.42.4. The results in Fig. 2b indi-
cated that 42.4 did not pull-down His-tagged CRBN
from either pCDH.CRBN or AGO2.pNUT cell lysates
(Fig. 2b), but clearly pulled-down the His-tagged CRBN
from AGO2.CRBN cell lysates (Fig. 2b). Subsequently,
these cell lysates were used to do Co-IP with our mouse
monoclonal antibody 2F11G5 which recognizes human
CRBN. The results in Fig. 2c clearly indicated that this
antibody pulled down CRBN and AGO2 from
AGO2.CRBN cell lysates, suggesting that AGO2 is a
CRBN downstream binding protein.
In order to confirm whether the un-tagged proteins
could also be co-IPed with mouse monoclonal
Table 1 Proteins pulled-down with Ni++ − charged beads
Proteins My5/LV cell lysates My5/CRBN cell lysates
CRBN 0a 28a
CUL-4B 0 6
AGO2 0 6
DDB1 6 81
CUL-4A 2 19
aThe number in each column represents the number of assigned spectra for
that protein
Fig. 1 Effects of lenalidomide on the MM cell lines with variant levels of CRBN. a Expression of CRBN in MM cell lines. 100 μg of total proteins
from whole cell lysates were loaded in each lane and probed with our recently developed mouse-anti-CRBN monoclonal antibody 2F11G5
(M-anti-CRBN) and mouse-anti-β-actin antibody (M-anti-β-Actin). b Comparison of CRBN expression in MM cell lines. The intensity of the β-
actin band was considered as 1.0 and the relative intensity of CRBN band was compared with its corresponding β-actin band. c. The effects of
lenalidomide on the MM cell lines. MM cells were plated in a volume of 200 μl at 10,000 cells per well in 96-well plate containing either
DMSO (DMSO-treated control viabilities were considered as 100 %) or 10 μM lenalidomide. Cell survival was followed by MTT assay
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antibody against CRBN, the cell lysates from MM cell
expressing higher level of CRBN (JJN3 in Fig. 1a and
b) or lower level of CRBN (My5.LV in Fig. 1a and b)
were used to do Co-IP with 2F11G5. The results in
Fig. 2d and e clearly indicated that 2F11G5 antibody
pulled-down endogenous CRBN and AGO2, further
confirming that AGO2 is a CRBN-downstream bind-
ing protein.
Lenalidomide treatment of MM cells affects the steady-
state levels of CRBN and AGO2
We and others have found that the treatment of MM
cells with IMiDs affected the steady-state levels of CRBN
and its downstream binding factors, such as IKZF1 and
IKZF3 [13–15, 20]. Based on these results, we speculated
that the treatment of MM cells with IMiDs should also
affect the steady-state levels of AGO2. In fact, the
steady-state levels of AGO2 in BHK cells expressing
both CRBN and AGO2 are significantly less than in
BHK cells expressing AGO2 along (Fig. 2a), suggesting
that CRBN may down-regulate AGO2. We then checked
the relative levels of AGO2 in lentiviral vector-treated
My5 cell or in CRBN cDNA-treated My5 cell (Fig. 3a)
and showed that the steady-state level of CRBN in
My5.CRBN cell is approximately 8 fold higher than in
My5.LV (Fig. 3b), whereas AGO2 in CRBN-high
My5.CRBN cell is approximately 30 % of CRBN-low
My5.LV (Fig. 3b), suggesting that CRBN may down-
regulate its downstream binding protein AGO2.
In order to test the effects of IMiDs on the steady-
state levels of AGO2, CRBN-low My5.LV and CRBN-
high My5.CRBN cells were treated with either dimethyl
sulfoxide (DMSO) or lenalidomide. It is clear, from the
results in Fig. 3c and e, that the steady-state levels of
CRBN, upon treatment of CRBN-low My5.LV cells with
10 μM lenalidomide, were slightly increased. However,
the steady-state levels of AGO2, upon treatment of
CRBN-low My5.LV cells with 10 μM lenalidomide, were
not significantly altered within 2 or 3 days incubation
(Fig. 3e and Additional file 1: Figure S3) and slightly de-
creased after 4 days (Fig. 3c and e). In contrast, although
CRBN in My5.CRBN cell is approximately 8 fold higher
than in My5.LV cell (Fig. 3b), the steady-state levels of
CRBN in lenalidomide treated CRBN-high My5.CRBN
cells is approximately five fold higher than the DMSO
treated cells (Fig. 3d and f ). Of note, although AGO2
in CRBN-high My5.CRBN cells is approximately 30 %
of CRBN-low My5.LV cells (Fig. 3b), the steady-state
levels of AGO2 in lenalidomide treated CRBN-high
My5.CRBN for 6 days is approximately 20 % of the
DMSO treated cells (Fig. 3f ). In addition, the treatment
of CRBN-low My5.LV or CRBN-high My5.CRBN cells
with lenalidomide for 6 days did not significantly alter
the levels of AGO2 mRNA or CRBN mRNA (Fig. 3g),
suggesting that lenalidomide post-translationally, in a
CRBN-dependent manner, modulates AGO2. Interest-
ingly, the treatment of MM1.S.Res cells, which express
undetectable amount of CRBN (Fig. 1a and b), with
lenalidomide for 6 days did not significantly affect the
steady-state levels of AGO2 (Fig. 3h), suggesting that
CRBN is required for lenalidomide-mediated degrad-
ation of AGO2.
Fig. 2 Validation of AGO2 as a CRBN-downstream binding protein. a Expression of His-tagged CRBN and MRP1 antibody 42.4 epitope-tagged
AGO2 in BHK cells. Total proteins from whole cell lysates were separated on an acrylamide gel and probed with mouse-anti MRP1 antibody 42.4
(42.4), M-anti-CRBN and M-anti-Actin antibodies. b Co-IP of CRBN with 42.4-tagged AGO2. Samples were IPed with 42.4 and probed with either
rabbit-anti-CRBN (R-anti-CRBN) or rabbit-anti-AGO2 (R-anti-AGO2). c Co-IP of 42.4-tagged AGO2 with CRBN. The three cell lysates mentioned above
were IPed with our mouse-anti-CRBN antibody 2F11G5 and probed with either rabbit-anti-CRBN or rabbit-anti-AGO2. d & e Co-IP of wild-type AGO2
with endogenous CRBN in JJN3 cell (d) and in My5.LV cell (e). Samples were IPed with our mouse-anti-CRBN antibody 2F11G5 and probed with either
rabbit-anti-AGO2 or rabbit-anti-CRBN. Input: whole cell lysates; IP: whole cell lysates immunoprecipitated (IPed) with M-anti-CRBN; Control: whole cell
lysates IPed with protein G beads without adding primary antibody; IB: samples probed with the antibodies indicated in the figure
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Degradation of AGO2 is directly associated with effective
CRBN
The results in Fig. 3 suggested that the binding of lenali-
domide to CRBN may prevent E3-CRBN-proteasome
mediated degradation of AGO2. In order to prove this
hypothesis, the CRBN-low My5.LV cells and CRBN-high
My5.CRBN cells were treated with lenalidomide and
proteasome inhibitor MG132 and the degradation prod-
ucts of AGO2 were monitored with AGO2 antibody in
western blots. It is clear that, upon treatment of CRBN-
low My5.LV cells or CRBN-high My5.CRBN cells for
24 hours, the accumulation of AGO2 degradation
Fig. 3 Lenalidomide treatment of MM cells affected the steady-state levels of CRBN and AGO2. a CRBN and AGO2 protein expression in My5.LV
cell or in My5.CRBN cell. 100 μg of total proteins from whole cell lysates were loaded in each lane and analyzed by western blot. b The steady-
state levels of AGO2, CRBN and β-actin were compared between My5.LV and My5.CRBN cells. c & d Relative levels of AGO2, CRBN and β-actin.
Cells were treated with either DMSO (control) or 10 μM lenalidomide (LEN) for the time indicated in the figure. 100 μg of total proteins from
My5.LV cells (c) or My5.CRBN cells (d) were loaded in each lane and analyzed by western blot. e & f Comparison of the protein expression
between the samples treated with either DMSO or lenalidomide. The steady-state levels of AGO2, CRBN and β-actin in My5.LV cells (e) or in
My5.CRBN cells (f) were compared between the treatments with either DMSO (considered as 1.0) or lenalidomide. g Quantitative analysis of
AGO2 mRNA or CRBN mRNA. Total RNA was isolated from My5.LV and My5.CRBN cells treated with either DMSO or 10 μM lenalidomide for six
days and used to do quantitative polymerase chain reaction (qPCR). h Relative levels of AGO2, CRBN and β-actin in MM1.S.Res cells treated with
either DMSO or 10 μM lenalidomide. MM1.S.Res cells were treated with either DMSO or 10 μM lenalidomide for six days. 100 μg of total proteins
from these treated cells were loaded in each lane and analyzed by western blot
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product (67 kDa) was significantly decreased (lane 2 in
Fig. 4a and b), suggesting that binding of lenalidomide
to CRBN not only prevents E3-CRBN-mediated ubiquiti-
nation of AGO2, but also proteasome-mediated degrad-
ation. The treatment of CRBN-low My5.LV cells with
proteasome inhibitor MG132 did not significantly
increased the accumulation of the 67 kDa AGO2 deg-
radation product (lane 3 in Fig. 4a), suggesting that E3-
CRBN-proteasome-mediated degradation of AGO2 in
CRBN-low My5.LV cells is not very efficient. This con-
clusion is supported by the result derived from My5.LV
cells treated with lenalidomide and MG132 (lane 4 in
Fig. 4a). In contrast, the treatment of CRBN-high
My5.CRBN cells with proteasome inhibitor MG132 did
significantly increase, regardless of whether lenalidomide
was added or not, the accumulation of the 67 kDa
AGO2 degradation product (lane 3 and 4 in Fig. 4b),
suggesting that lenalidomide-free CRBN in CRBN-high
My5.CRBN cells can recruit AGO2 for E3-CRBN-
proteasome-mediated degradation.
The results in Fig. 3, upon treatment of MM cells with
lenalidomide for 6 days, suggested that AGO2 degrad-
ation might be directly associated with the amount of
lenalidomide-free CRBN in MM cells. In order to prove
this hypothesis, the degradation products of AGO2,
upon treatment of the CRBN-low My5.LV cells or
CRBN-high My5.CRBN cells with lenalidomide for
6 days, were monitored with AGO2 antibody in western
blots. It is clear that, upon treatment of MM cells with
lenalidomide for 6 days, the accumulation of the 67 kDa
AGO2 degradation product in CRBN-low My5.LV cells
was slightly increased (lane 2 in Fig. 4c), whereas the ac-
cumulation of this degradation product in CRBN-high
My5.CRBN cells was significantly increased (lane 2 in
Fig. 4d), suggesting that the treatment with lenalidomide
for 6 days accumulated much more lenalidomide-free
CRBN in CRBN-high My5.CRBN cells than in CRBN-
low My5.LV cells. Interestingly, although most of the
AGO2 protein in CRBN-high My5.CRBN cells were de-
graded upon treatment with lenalidomide for 6 days
(Fig. 3d and f ), the treatment with proteasome inhibitor
MG132 significantly increased the accumulation of the
67 kDa AGO2 degradation product (lane 4 in Fig. 4d),
suggesting that the treatment with lenalidomide for
6 days accumulated much more lenalidomide-free
CRBN in CRBN-high My5.CRBN cells than in CRBN-
low My5.LV cells. These results support our hypothesis
that the E3-CRBN-proteasome-mediated degradation of
Fig. 4 Lenalidomide treatment of MM cells affected degradation of AGO2. a & b The effects of lenalidomide treatment of My5.LV cells (a) or
My5.CRBN cells (b) for 1 day. MM cells were treated with either DMSO (−) or 10 μM lenalidomide (+) for 18 hours and then 10 μM proteasome
inhibitor MG132 (+) were added to the media for additional 6 hours. c & d The effects of lenalidomide treatment of My5.LV cells (c) or My5.CRBN
cells (d) for 6 days. MM cells were treated with either DMSO (−) or 10 μM lenalidomide (+) for 138 hours and then 10 μM proteasome inhibitor
MG132 (+) were added to the media for additional 6 hours. 100 μg of total proteins from whole cell lysates were loaded in each lane and analyzed by
western blot. The intensity of β-actin band or the 67 kDa AGO2 degradation product in samples neither treated with lenalidomide nor MG132 was
considered as 1 and the relative amount of β-actin or the 67 kDa AGO2 degradation product in other samples was calculated accordingly
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AGO2 is directly associated with lenalidomide-free
CRBN or effective CRBN.
The effects of AGO2-shRNA treatment on MM cells
We have noticed that it took days to decrease the
steady-state levels of AGO2 (Fig. 3) and wondered
whether this is related to the slow process of
lenalidomide-induced MM cell death (Fig. 1c). To test
this hypothesis, AGO2-shRNAs and AGO2 itself were
used to treat the AGO2-high My5.LV cells and AGO2-
low My5.CRBN cells.
Interestingly, the treatment of My5.LV or My5.CRBN
cells with pLKO.1 vector or pCDH.puro vector did not
have a significant effect on cell growth and survival,
whereas the treatment with AGO2-shRNA, especially
the treatment with sh72 and sh74, decreased the levels
of AGO2 (Fig. 5c and d), and induced cell death (Fig. 5a
and b), regardless of their sensitivity to IMiDs (Fig. 1c).
The treatment of other MM cell lines, such as JJN3,
OPM1, MM1.S and MM1.S.Res, with AGO2-sh72 also
induced cell death (Fig. 5e). Although the treatment of
My5.LV and My5.CRBN cells with AGO2 cDNA in-
creased the steady-state levels of AGO2 (Fig. 5c and d),
this treatment did not have a significant effect on cell
growth and survival (Fig. 5a and b), but slightly increased
IC50 value of lenalidomide for IMiD-sensitive My5.CRBN
cells (Additional file 1: Figure S7). However, the treatment
of AGO2-sh72 treated My5.LV or My5.CRBN cells with
AGO2 cDNA did increase their growth and survival
(Fig. 5f ). Of note, the growth rate of the MM cells ex-
pressing higher levels of CRBN is lower than the cells
with lower levels of CRBN (Additional file 1: Figure
S4A, S4B and S4C). In addition, the cytotoxicities in-
duced by the treatment with AGO2-shRNA in AGO2-
low My5.CRBN cells occurred much earlier than in
AGO2-high My5.LV cells (Additional file 1: Figure
S4D), suggesting that it might take longer time to de-
crease the AGO2 level in AGO2-high My5.LV cells to
a critical point to inhibit cell growth or to induce
cell death.
Fig. 5 Silencing of AGO2 induced cytotoxicity in IMiD-resistant and IMiD-sensitive MM cells. a & b The effects of silencing AGO2 with AGO2-
shRNA on MM cell growth and survival. IMiD-resistant My5.LV cells (a) and IMiD-sensitive My5.CRBN cells (b) were infected with lentiviral particles
harboring either lentiviral vector, AGO2-shRNA or AGO2 cDNA. The media were replaced 18 hours post-infection and then 1 μM puromycin (final
concentration) was added 24 hours later (day0). Cell survival was followed by MTT assay. c & d The effects of silencing AGO2 with AGO2-shRNA
on the steady-state levels of AGO2, CRBN and β-actin. IMiD-resistant My5.LV cells (c) and IMiD-sensitive My5.CRBN cells (d) were lysed three days
post infection with viral particles indicated in (a) and (b) and 100 μg of total proteins from these treated cells were loaded in each lane and
analyzed by western blot. e The effects of silencing AGO2 with AGO2-shRNA on other MM cell lines. f Expression of recombinant AGO2 can
reverse the AGO2.shRNA induced cytotoxicity. The infection of My5.LV and My5.CRBN cells with viral particles harboring AGO2-shRNA-72 was
performed exactly the same as in (a) and (b) The rescue experiments were performed by: 1) collecting the MM cells treated with AGO2-
shRNA-72 for six days; 2) infecting these cells with viral particles harboring AGO2 cDNA; 3) replacing the media 18 hours post-infection; 4)
performing MTT assay 24 hours later (day1)
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Reducing the expression of AGO2 affected steady-state
levels of microRNAs
AGO2 is considered as a master regulator of miRNA
maturation and function [17–19]. In order to test the ef-
fects of altering the levels of AGO2 on miRNAs, total
RNAs were isolated and used to determine the steady-
state levels of 372 miRNAs. The results in Fig. 6a indi-
cated that, without any treatment, majority of the
miRNAs in My5.LV cell were similar to that in
My5.CRBN cell. However, the steady-state levels of 88
Fig. 6 Silencing of AGO2 with its shRNA altered the steady-state levels of miRNAs. Total RNAs were isolated from MM cells treated with either AGO2-
shRNA72 (sh72) or AGO2 cDNA (AGO2) for three days and the steady-state levels of miRNAs were analyzed with microRNA array kit. a Comparison of
the steady-state levels of miRNAs between My5.LV and My5.CRBN cells; b between My5.LV and sh72 treated My5.LV cells (My5.LV.sh72); c between
sh72 treated My5.LV (My5.LV.sh72) and AGO2 treated My5.LV cells (My5.LV.AGO2); d between My5.CRBN and sh72 treated My5.CRBN cells
(My5.CRBN.sh72); e between AGO2-sh72 treated My5.CRBN (My5.CRBN.sh72) and AGO2 treated My5.CRBN cells (My5.CRBN.AGO2)
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miRNAs in AGO2-sh72 treated My5.LV cells were at
least 3 fold lower than in the un-treated My5.CRBN
cells (Additional file 1: Figure S5F), suggesting that si-
lencing of AGO2 decreased the stability of miRNAs.
This conclusion is further supported by the compari-
son between the un-treated and AGO2-sh72-treated
My5.LV cells (Fig. 6b and Additional file 1: Figure
S5C). In contrast, increasing the level of AGO2, by
treatment of My5.LV cells with AGO2 cDNA, signifi-
cantly enhanced the steady-state levels of many miR-
NAs (Additional file 1: Figure S5B). Interestingly, if
the comparison is done between AGO2-sh72 treated
My5.LV cells and AGO2 cDNA treated My5.LV cells,
majority of the miRNAs were increased (Fig. 5c and
Additional file 1: Figure S5D), suggesting that the sta-
bilities of miRNAs in MM cells are associated with the
intracellular levels of AGO2.
For cells expressing higher level of CRBN, such as
My5.CRBN, CRBN may play an important role in regu-
lating the intracellular levels of AGO2 (Figs. 2a and 3a).
Decreasing the level of AGO2 by treatment with AGO2-
sh72 resulted in decreasing many miRNAs for at least 3
fold (Fig. 6d and Additional file 1: Figure S5E). In con-
trast, increasing the level of AGO2, by the treatment of
My5.CRBN cells with AGO2 cDNA, significantly en-
hanced the steady-state levels of miRNAs (Fig. 6e and
Additional file 1: Figure S5H). In summary, higher levels
of AGO2 resulted in enhanced levels of many miRNAs
whereas reduced levels of this protein lead to decreased
levels of many miRNAs, as shown in Additional file 2:
Table S3 and Additional file 1: Figure S5.
Treatment of MM cells with lenalidomide significantly
affects steady-state levels of miRNAs
Since the degradation of AGO2 was associated with the
time of lenalidomide treatment (Fig. 3e and f), the ef-
fects of IMiD on the steady-state levels of miRNAs
should also be associated with incubation time. For ex-
ample, upon treatment of IMiD-resistant My5.LV cells
with 10 μM lenalidomide for 3 days, the levels of AGO2
were not significantly affected, whereas this protein
dropped to ~ 80 % after 5 days (Fig. 3e). Interestingly,
the levels of miRNAs were not significantly affected
after 3 days treatment with lenalidomide (Fig. 7a),
whereas many miRNAs were either up- or down-
regulated at least 3 fold after 5 days treatment (Fig. 7b
and Additional file 1: Figure S6A), suggesting that miR-
NAs’ stability is related to the intracellular levels of
AGO2. In the case of IMiD-sensitive My5.CRBN cells,
many miRNAs were up-regulated at least 3 fold after
3 days treatment with lenalidomide (Fig. 7c and Additional
file 1: Figure S6Q), whereas treatment for 5 days resulted
in down-regulating many miRNAs (Fig. 7d and Additional
file 1: Figure S6J). These results are consistent with our
notion that higher levels of AGO2 mainly up-regulate
miRNAs whereas lower levels of this protein primarily
down-regulate miRNAs (Fig. 6). Further comparison of
the samples treated with lenalidomide for 5 days with
other samples (Additional file 2: Table S4 and Additional
file 1: Figure S6B-S6I and S6K-S6Q) strongly supported
the above conclusion.
Treatment of MM cells, regardless of their IMiD-
sensitivities, with AGO2-shRNA induced apoptosis
Based on our results presented above, we hypothesized
that: 1) the interaction between IMiDs and CRBN will
inhibit degradation of CRBN, leading to enhanced
steady-state levels of CRBN (Fig. 3); 2) the enhanced
steady-state levels of CRBN, once the bound IMiDs are
dissociated, will recruit AGO2 for E3 ubiquitin ligase-
proteasome mediated degradation; 3) the enhanced deg-
radation of AGO2 will decrease the steady-state levels of
AGO2 to a critical point that leads to decrease the sta-
bility of miRNAs; 4) some of the decreased miRNAs
may be responsible for the expression of the proteins as-
sociated with cell growth, survival and apoptosis; 5)
treatment of MM cells, regardless of their sensitivities to
IMiDs, with AGO2-shRNA should induce apoptosis. To
test this hypothesis, the five MM cell lines used in Fig. 1
were treated with either 10 μM lenalidomide or AGO2-
shRNA-74 and analyzed with an Alexa Fluor 647
Annexin V kit to determine the percentage of live cells,
apoptotic cells and necrotic cells (Fig. 8a).
It is clear that the treatment of CRBN-low MM cells,
such as My5.LV or MM1.S.Res (Fig. 1a and b), with
10 μM lenalidomide did not induce apoptosis (Fig. 8b),
whereas the treatment of CRBN-high MM cells, such as
My5.CRBN, JJN3 or MM1.S (Fig. 1a and b), with 10 μM
lenalidomide significantly induced apoptosis (Fig. 8b). In
contrast, the treatment of MM cells, regardless of their
steady-state levels of CRBN, with AGO2-shRNA-74 sig-
nificantly induced apoptosis (Fig. 8c), suggesting that
AGO2 could be considered as a novel drug target to
overcome IMiD resistance.
Discussion and Conclusions
We have identified AGO2 as a CRBN-downstream
binding protein. This conclusion is based on: 1) AGO2
was pulled down with His-tagged CRBN (Table 1 and
Additional file 2: Table S2); 2) CRBN was co-IPed with
42.4-tagged AGO2 (Fig. 2b); 3) 42.4-tagged AGO2 was
co-IPed with CRBN (Fig. 2c); 4) endogenous AGO2 was
co-IPed with wild-type CRBN (Fig. 2d and e); 5) the
steady-state levels of AGO2 in CRBN-high MM cells
are significantly lower than the corresponding CRBN-
low MM cells (Figs. 2a and 3a); and 6) treatment of
MM cells with lenalidomide affects the steady-state
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levels of AGO2 (Fig. 3c, d, e and f ) and miRNAs (Fig. 7b
and d).
AGO2 is considered as a master regulator of miRNA
maturation and function [17–19, 23–25] and miRNAs
regulate up to 90 % of human genes via a silencing
process mediated by miRNA-induced silencing com-
plexes (miRISCs) [23]. Dysregulation of miRNAs is asso-
ciated with cancer initiation and progression [26, 27]. It
has been found that: 1) miR-125b induced myeloid
leukemia by enhancing myeloid progenitor output from
stem cells as well as inducing immortality, self-renewal
and tumorigenesis in myeloid progenitors [28]; 2) high-
risk myeloma is associated with global elevation of
miRNAs and over-expression of AGO2 [29]; and 3)
over-expression of AGO2 resulted in increased miRNA
accumulation [17, 30]. However, the mechanism of
AGO2 regulation is largely un-known. Now we have
found that AGO2 is a CRBN-downstream binding fac-
tor that is tightly regulated by the effective CRBN
(Fig. 4) at the post-translational level. In addition, we
have found that the steady-state levels of AGO2 in
CRBN-high MM cells are significantly lower than the
corresponding CRBN-low MM cells. Therefore, dysreg-
ulation of CRBN in cancer cells is responsible for mal-
functions of AGO2 and miRNAs.
It has been reported that IMiDs decreased the expres-
sion of vascular endothelial growth factor and basic
fibroblast growth factor [31], thereby inhibiting new
blood vessel formation and decreasing the tumor
growth. Indeed, microvessel growth in the IMiDs treated
samples was significantly less than in the corresponding
controls [32–37]. However, the molecular mechanism of
IMiD-induced anti-angiogenic effects is not well docu-
mented. Recent finding indicated that over-expression of
AGO2 increased angiogenesis, via regulation of miRNA
levels, whereas silencing of AGO2 inhibited angiogenesis
[38]. We have found, in this report, that AGO2 is a
CRBN-downstream binding protein and the treatment of
Fig. 7 Treatment of MM cells with lenalidomide altered steady-state levels of miRNAs. Total RNAs were isolated at day 3 or day 5 post 10 μM
lenalidomide treatment and the steady-state levels of miRNAs were analyzed with microRNA array kit. a Comparison of the steady-state levels of
miRNAs between My5.LV and My5.LV treated with 10 μM lenalidomide for 3 days; b between My5.LV and My5.LV treated with 10 μM lenalidomide for
5 days; c between My5.CRBN and My5.CRBN treated with 10 μM lenalidomide for 3 days; d between My5.CRBN and My5.CRBN treated with 10 μM
lenalidomide for 5 days
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MM cells with lenalidomide for 5 days resulted in de-
creased both AGO2 (Fig. 3) and miRNAs (Fig. 7), indi-
cating that IMiD-induced anti-angiogenic effects may go
through CRBN-AGO2-miRNA pathway.
We conclude that AGO2 plays an important role in
regulating MM cell growth and survival. This conclusion
is based on our finding that silencing AGO2 expression
halted MM cell growth (Fig. 5a and b). In other words,
MM cell growth requires higher levels of AGO2. Based
on this conclusion, we predicted that the growth rate of
My5.LV cells, which have significant higher levels of
AGO2 than My5.CRBN cells (Fig. 3a and b), should be
higher than that of My5.CRBN cells. Indeed, the growth
rates of pLKO.1- and pCDH-treated My5.LV cells were
significantly higher than the corresponding treated
My5.CRBN cells (Additional file 1: Figure S4A and S4B).
In addition, the growth rate of AGO2-cDNA-treated
My5.LV cells was significantly higher than the
corresponding treated My5.CRBN cells (Additional file
1: Figure S4C), implying that the steady-state levels of
AGO2 might be controlled by CRBN. Furthermore, the
cell survival of the AGO2-high My5.LV cells, upon treat-
ment with AGO2-sh72, is significantly higher than the
AGO2-low My5.CRBN cells treated with the same
shRNA (Additional file 1: Figure S4D), suggesting that it
may take longer time to decrease the endogenous AGO2
to a critical point to inhibit cell growth in AGO2-high
My5.LV cells than in AGO2-low My5.CRBN cells.
One puzzle we had in the past is that the time of
IMiD-induced IKZF1 or IKZF3 degradation (within
hours) and IMiD-induced cytotoxicity (days) is not tem-
porally consistent. IKZFs are zinc finger transcription
factors that play important roles in lymphocyte differen-
tiation [39, 40]. Treatment with IMiDs or IKZF-shRNA
not only induced fast-degradation of IKZFs [13–15, 20],
but also modulate, within relatively short time, the
Fig. 8 Treatment of MM cells, regardless of their IMiD-sensitivities, with AGO2-shRNA induced apoptosis. a Profiles for apoptosis analysis with Alexa
Fluor 647 Annexin V. MM cells were treated with either DMSO (as a control) or 10 μM lenalidomide (LEN) for six days; or with either lentiviral vector (as
a control) or AGO2-shRNA74 (sh74) for four days, respectively. The cells were stained with annexin V-Alexa Flour 647 and 0.5 mg/mL propidium iodide
(PI) and then analyzed by flow cytometry. Region 1 indicates the live cells; 2, necrotic cells; 3, late apoptotic cells; 4, early apoptotic cells. b Effects of
lenalidomide on MM cells. Annexin V+ indicates annexin V positive cells. PI+ indicates propidium iodide positive cells. The bar graph indicates the
mean ± standard deviation. *P value < 0.05; **P value < 0.01. c Effects of AGO2-shRNA74 on MM cells
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expression of their downstream factors, such as inter-
feron regulatory factor 4 (IRF4) [13, 15] or interleukin-2
(IL-2) [20]. However, the time required for IKZF-
shRNA-induced cytotoxicity was significantly longer
than the time of IMiD-induced cell death [13, 14], im-
plying that there might be other CRBN binding factors
that participate in IMiD-induced cytotoxicity. We have
found that AGO2 is a CRBN binding factor that is
modulated by lenalidomide. AGO2 is a critical compo-
nent of miRISCs that modulate a wide variety of pro-
tein syntheses at translational level. Interestingly, the
time of lenalidomide-induced degradation of AGO2
(Fig. 3f ) is consistent with lenalidomide-induced alter-
ation of miRNAs (Fig. 7c and d). In addition, the time
of lenalidomide-induced alteration of miRNAs (Fig. 7c
and d) is also more or less consistent with the time of
lenalidomide induced cell death (Fig. 1c). Therefore, al-
though detailed mechanism of IMiD-induced cell death
is not clear yet, part of the IMiD-induced cell death
may go through CRBN-AGO2-miRNAs pathway.
The conclusion made in previous paragraph elicited a
question of whether AGO2 is the sole factor responsible
for the early onset of IMiD-induced cytotoxicity. We
have found that: 1) the steady-state levels of AGO2 in
IMiD-resistant My5.LV cells, upon treatment with lenali-
domide, were not significantly affected (Fig. 3e and g); 2)
the treatment of IMiD-resistant My5.LV cells with
10 μM lenalidomide for 3 days did not significantly alter
the steady-state levels of miRNAs (Fig. 7a). Therefore,
these results are consistent with IMiD-resistance of
My5.LV cells (Fig. 1c). However, we have also found that,
upon treatment of My5.LV cells with 10 μM lenalido-
mide for 5 days, the steady-state levels of some miRNAs
were significantly down-regulated (Fig. 7b). This fact is
more or less consistent with lenalidomide-induced
moderate down-regulation of AGO2 (Fig. 3e) and mild
cytotoxicity (Additional file 1: Figure S1). One possible
explanation for this fact is that lenalidomide treatment
for 5 days did not decrease the levels of critical miR-
NAs to a threshold to massively trigger apoptosis in
those MM cells expressing low levels of CRBN. How-
ever, in considering the following observations: 1) the
miRNAs altered by the treatment with AGO2-sh72 are
not exactly the same as the treatment with lenalido-
mide (Fig. 6b versus Fig. 7b or Fig. 6d versus Fig. 7d or
Additional file 1: Figure S5 versus S6); 2) the proteins
altered by the treatment with AGO2-sh72 are not
exactly the same as the treatment with lenalidomide
[For example, IKZF1 or IKZF3 in My5.CRBN cells was
significantly increased upon treatment with AGO2-
sh72, whereas these proteins were significantly de-
creased upon treatment with lenalidomide (data not
shown)]; 3) slightly different response of My5.LV and
My5.CRBN cells to AGO2-shRNAs was observed
(Additional file 1: Figure S4D); we cannot rule out the
possibility that some other un-identified CRBN-
downstream binding factors may also participate in
IMiD-induced cytotoxicity. In addition, the effects oc-
curred within the first two or three days of lenalido-
mide treatment may not be directly associated with
AGO2 (Figs. 1c and 5). Furthermore, although the sen-
sitivity of MM cells to lenalidomide is associated with:
1) the intracellular levels of CRBN (Fig. 1); 2) the differ-
ential regulation of miRNAs, upon treatment with lena-
lidomide, in MM cells with variant levels of CRBN
(Additional file 1: Figure S6R and S6S), the detailed
molecular mechanism of lenalidomide induced cell
death is not clear yet.
It is clear that IMiD binding to CRBN enhanced accu-
mulation of CRBN, especially in IMiD-sensitive cells
(Fig. 3f ), and eventually resulted in decreased levels of
AGO2 (Fig. 3). The decreased levels of AGO2 (Fig. 3
and 5) resulted in down-regulation of miRNAs (Fig. 6
and 7) that further affected protein syntheses. It is not
clear, however, which protein synthesis is affected by the
decreased levels of miRNAs. It has been reported that si-
lencing of AGO2 with its shRNA enhanced protein ex-
pression of cyclin-dependent kinase (CDK) inhibitors
p21Waf1/Cip1 and p27Kip1 [29]. Since these proteins
are CDK inhibitors, enhanced expression of these pro-
teins will inhibit CDKs and result in enhanced cell cycle
arrest [29]. Enhanced expression of p21Waf1/Cip1 might
be regulated by decreased level of miR-106 [29]. Indeed,
the steady-state levels of miR-106a-3p and miR-106b-3p
were significantly reduced upon treatment of the MM
cells with lenalidomide for 5 days (Additional file 1:
Figure S6C, S6D, S6G, S6K, S6L, and S6O). In fact,
many miRNAs were either up-regulated or down-
regulated at least 4 fold upon treatment of the MM
cells with either AGO2-shRNA or lenalidomide (Add-
itional file 2: Tables S3 and S4). Although we still don’t
know how many proteins were up- or down-regulated
upon these treatments, the treatment of IMiD-resistant
or IMiD-sensitive MM cells (Fig. 1c) with AGO2-
shRNA strongly inhibited cell growth and induced cell
death (Figs. 5 and 8). Therefore, AGO2 could be con-
sidered as a novel therapeutic target for overcoming
IMiD-resistance in MM cells.
Methods
Cell culture
Human MM cell lines were maintained in RPMI-1640
medium (Thermo Scientific) supplemented with 10 %
heat-inactivated fetal bovine serum (Thermo Scientific)
and 1 % penicillin/streptomycin. BHK cells were cul-
tured in DMEM/F12 medium (Thermo Scientific) sup-
plemented with 5 % fetal bovine serum and 1 %
penicillin/streptomycin.
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Pull-down His-tagged CRBN and its associated proteins
10 histidine residues were introduced into the C-
terminus of human CRBN cDNA by polymerase chain
reaction (PCR) and then cloned into pCDH-CMV-MCS-
EF1-copGFP (green fluorescent protein) expression vec-
tor (System Bioscience, Mountain view, CA), named as
pCDH.GFP.CRBN.His. Lentiviral particles harboring the
cloning vector and pCDH.GFP.CRBN.His were prepared,
according to the method described [41], and used to in-
fect human myeloma OCI-My5 (My5) cells to generate
control cell line My5.LV and CRBN expressing cell line
My5.CRBN.His. The infected MM cells were sorted for
GFP expression at day 14 after infection.
My5.LV and My5.CRBN.His cells were grown up in
RPMI-1640 medium at 37 °C, treated with 2 mM so-
dium butyrate for overnight before harvesting, harvested
by centrifugation and stored at - 80 °C. The cell pellets
were re-suspended in 1 × binding buffer (20 mM Tris/
HCl, pH7.9; 500 mM NaCl; and 10 % glycerol) with pro-
tease inhibitors and then equilibrated on ice for 30 mi-
nutes at 800 p.s.i. in a Parr nitrogen cavitation bomb
[22]. After releasing the pressure, the cell lysates were
centrifuged at 33,000 × g for 30 minutes at 4 °C to col-
lect supernatant. The pellet was re-suspended in 1 × bind-
ing buffer, sonicated for 20 pulses on ice and centrifuged
at 33,000 × g for 30 minutes at 4 °C to collect supernatant.
The two supernatants were combined and the protein
concentration of the supernatants was determined. Equal
amount of proteins from My5.LV supernatant or
My5.CRBN.His supernatant were mixed, in two separated
tubes, with similar amount of nickel-charged NTA (Ni-
NTA) agarose beads, adjusted to have 5 mM imidazole,
and gently rotated on a rocker overnight at 4 °C. The
loaded Ni-NTA agarose beads were packed into a column
(in two separated columns) and washed with 1 × binding
buffer containing 10 mM imidazole (1st wash), 20 mM
imidazole (2nd wash) and 40 mM imidazole (3rd wash)
[42]. The bound proteins were eluted with 1 ×binding buf-
fer containing 100 mM EDTA.
Tandem mass spectrometry (MS/MS) analysis
For the proteomics experiments, the proteins pulled-
down with nickel-charged NTA agarose beads were re-
solved by a 10 % sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). The gel bands (10 gel
bands per lane) were excised and destained, digested
with trypsin, and desalted using ZipTips (Millipore, Bil-
lerica, MA) as previously described [43]. HPLC-ESI-MS/
MS analysis was performed on a Thermo Scientific Orbi-
trap Elite Velos Pro fitted with an EASY-Spray Ion
Source (Thermo Scientfic, Waltham, MA). On-line
HPLC was performed using a Thermo Scientific Dionex
Ultimate 3000 Series Nano/Cap System NCS-3500RS
nanoLC with an Acclaim PepMap100 trap column
(ThermoScientific, 75 μm ID ×2 cm, 3 μm C18, 100 Å)
and an Acclaim PepMap RSLC analytical column (Ther-
moScientific, 75 μm ID ×15 cm, 2 μm C18, 100 Å); load-
ing was performed at flow rate of 6 nl/min, and elution
was performed at a gradient of 2 to 35 % Buffer B for
65 minutes, followed by a step to 90 % Buffer B and a
hold for 5 minutes, followed by a return to 4 % Buffer B
(Buffer A: 0.1 % formic acid in water, Buffer B: 80 %
acetonitrile in 0.1 % formic acid and water); analytical
flow rate, 300 nl/min. A “top-10” data-dependent MS/
MS analysis was performed (acquisition of a full scan
spectrum followed by collision-induced dissociation
mass spectra of the 10 most abundant ions in the survey
scan). The fragment mass spectra were then searched
against the human SwissProt_2013_02 database (539,165
entries) using Mascot (Matrix Science, London, UK; ver-
sion 2.4). The search variables used were: 1) 10 ppm
mass tolerance for precursor ion masses and 0.5 Da for
product ion masses; 2) digestion with trypsin; 3) a max-
imum of two missed tryptic cleavages; 4) variable
modifications of oxidation of methionine and phosphor-
ylation of serine, threonine, and tyrosine. Cross-
correlation of Mascot search results with X! Tandem
was accomplished with Scaffold (version Scaffold_4.2.1;
Proteome Software, Portland, OR, USA). Probability of
peptide assignments and protein identifications were
made through the use of Scaffold. Only peptides with ≥
95 % probability were considered.
Validation of AGO2 as a CRBN downstream binding
protein
In order to validate AGO2 as a CRBN binding pro-
tein, the epitope of 42.4 antibody, a multidrug
resistance-associated protein 1 (MRP1) antibody [22],
was introduced into the C-terminus of human AGO2
cDNA (from DNASU, Tempe, AZ) by PCR and then
cloned into the pCDH-CMV-MCS-EF1-copGFP ex-
pression vector that provides GFP expression, named
as pCDH.GFP.AGO2.42.4. In the meantime, the 10
His-tagged human CRBN cDNA was shifted from
pCDH.GFP.CRBN.His to pNUT expression vector
[44, 45], named as pNUT.CRBN.His.
Three cell lines had been established by introducing,
via calcium phosphate transfection method [42], the fol-
lowing pairs of DNAs: 1) pCDH.GFP.AGO2.42.4 +
pNUT (named as AGO2/pNUT); 2) pCDH-CMV-MCS-
EF1-copGFP + pNUT.CRBN.His (named as pCDH/
CRBN); 3) pCDH.GFP.AGO2.42.4 + pNUT.CRBN.His
(named as AGO2/CRBN), into BHK cells [22]. Permanent
cell lines were established by selection with 100 μM MTX.
For co-immunoprecipitation (Co-IP) of CRBN with
AGO2, the aforementioned three BHK cell lines were
lysed with NP40 lysis buffer (0.1 % NP40; 150 mM NaCl;
10 mM NaMoO4• 2H20; and 50 mM Tris–HCl, pH7.6),
Xu et al. BMC Cancer  (2016) 16:297 Page 13 of 16
supplemented with 1 ×protease inhibitor cocktail con-
taining: Aprotonin, 2 μg/mL; Benzamide, 121 μg/mL;
E64, 3.5 μg/mL; Leupeptin, 1 μg/mL; and Pefabloc,
50 μg/mL. Primary antibody, after pre-cleaning with pro-
tein G beads (Invitrogen), was added to the cell lysates
and gently rotated overnight at 4 °C. Protein G beads
were added to the antibody treated cell lysates and
washed with NP40 cell lysis buffer three times. The
bound proteins were eluted with 45 μL of 2 ×SDS-PAGE
loading buffer at 90 °C for 10 minutes.
To Co-IP of AGO2 with CRBN, the cell lysates pre-
pared from My5.LV and JJN3 MM cell lines were IPed
with our recently made anti-human CRBN monoclonal
antibody 2F11G5.
Immunoblotting
Western blot was performed according to the routine
protocol. Briefly, equal amounts of proteins were sub-
jected to SDS-PAGE, followed by transferring the pro-
teins to nitrocellulose membranes, probed with primary
antibody overnight at 4 °C, washed with phosphate buff-
ered saline containing 0.1 % Tween-20 and then incubated
with appropriate horseradish peroxidase-conjugated sec-
ondary antibody. Chemiluminescent film detection was
performed according to the manufacturer’s recommenda-
tion. Anti-human CRBN mouse monoclonal antibodies,
2B11G10 and 2F11G5, were made by ourselves (through
GenScript). Rabbit-anti-CRBN antibody was purchased
from Sigma, whereas rabbit-anti-AGO2 antibody or other
antibodies were from Cell Signaling Technology.
MTT assay
Cell viability was measured by employing 3–(4,5-dimethyl-
thiazol-2-yl)–2,5-diphenyltetrazolium bromide (MTT) dye
(Sigma-Aldrich) performed according to the method de-
scribed [42, 46].
Modulating the expression of human AGO2 in MM cells
The 42.4-tagged AGO2 cDNA was shifted from
pCDH.GFP.AGO2.42.4 to pCDH-CMV-MCS-EF1-Puro,
named as pCDH.puro.AGO2.42.4, and used to make len-
tiviral particles, according to the routine method.
AGO2-shRNA constructs were purchased from Sigma-
Aldrich (The sequences of the shRNAs are shown in
Additional file 2: Table S1) and used to make lentiviral
particles. In the meantime, pLKO.1, the vector which
harbored AGO2-shRNAs, and pCDH-CMV-MCS-EF1-
Puro, the vector which harbored 42.4-tagged AGO2
cDNA, were also used to make lentiviral particles. These
viral particles were used to infect My5.LV or
My5.CRBN.His cells and selected with 1 μM puromycin,
performed according to the routine method.
MicroRNA array (miRNA array) and quantitative
polymerase chain reaction (qPCR)
For miRNA array, total RNA was isolated from My5
cells with miRNeasy Mini kit (QIAGEN). Reverse tran-
scription was performed with miScript II RT kit (QIA-
GEN), according to the protocol provided by QIAGEN.
Quantitative analysis of miRNA was performed with
miScript SYBR Green PCR Kit (QIAGEN) and miScript
miRNA PCR Arrays (QIAGEN), performed with our Ap-
plied Biosystems 7900HT Fast Real-Time PCR System,
according to the protocol provided by the manufacturer.
Data analyses were performed with QIAGEN online
software. The miRNA array data presented in this manu-
script have been deposited in the NCBI GEO database
(accession no. GSE61693).
For qPCR, total RNA was used to do qPCR with either
CRBN primers (forward: 5’-CAGTCTGCCGACATCAC
ATAC; reverse: 5’-GCACCATACTGACTTCTTGAG
GG) or AGO2 primers (forward: 5’-TCCACCTAGA
CCCGACTTTGG; reverse: 5’-GTGTTCCACGATTTCC
CTGTT).
Apoptosis analysis
The Alexa Fluor 647 Annexin V kit (BioLegend) was
used for detecting early apoptotic cells, late stage apop-
totic cells, necrotic cells and live cells, performed ac-
cording to the manufacture’s instructions.
Statistical analysis
Mean values and two-tailed P values were calculated
based on the unpaired t test from GraphPad Software
Quick Calcs. By conventional criteria, if P value is less
than 0.05, the difference between two samples is consid-
ered to be statistically significant.
Availability of data and materials
The miRNA array datasets supporting the conclusions of
this article are available in the NCBI GEO database (Ac-
cession no. GSE61693 and hyperlink to datasets in http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61693).
The datasets supporting the conclusions of this article
are included within the article and its additional files.
Additional files
Additional file 1: Figure S1. Lenalidomide induced cell death is a slow
process. Cell survival was monitored by MTT assay. Figure S2. Co-transfection
of pCDH.GFP.AGO2 with pNUT.CRBN.His yielded methotrexate (MTX)-resistant
cells that express high levels of GFP. Pictures were taken from MTX-
selected BHK cells that were transfected with the mixed DNAs containing
pCDH.GFP.AGO2 and pNUT.CRBN.His. Figure S3. AGO2 expression is
associated with cell growth. Cell lysates were harvested from My5.LV
without any treatment (−), treated with dimethyl sulfoxide (DMSO) or
10 μM lenalidomide (LEN) and analyzed by western blot (probed with
AGO2-specific antibody). Figure S4. The growth rate of the MM cells
with higher levels of CRBN is lower than the cells with low levels of
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CRBN. Cell survival, after infection of My5.LV or My5.CRBN.His cells with
viral particles containing pCDH vector (A), AGO2 cDNA (B), pLKO.1 vector (C)
or AGO2-shRNA-72 (D), was followed by MTT assay. Figure S5. Silencing of
AGO2 with its shRNA or over-expression of AGO2 altered the steady-state
levels of miRNAs. Total RNAs were isolated after AGO-shRNA72 (sh72)
treatment for 3 days or over-expression of AGO2 and the steady-state
levels of miRNAs were analyzed with microRNA array kit. Scatter plots
(a), heat-maps (b) and up- or down-regulated miRNAs (c) were established
by comparison of the steady-state levels of miRNAs between two samples
listed in each plot. Figure S6. Treatment of MM cells with lenalidomide
altered steady-state levels of miRNAs. Total RNAs were isolated after
lenalidomide treatment for 3 or 5 days and the steady-state levels of
miRNAs were analyzed with microRNA array kit. Scatter plots (a), heat-
maps (b) and up- or down-regulated miRNAs (c) were established by
comparison of the steady-state levels of miRNAs between two samples
listed in each plot. DOCX 5669 kb)
Additional file 2: Table S1. Sequence of human AGO2 small hairpin
RNA (shRNA). Table S2. Proteins detected by tandem mass spectrometry
analyses. Table S3. The miRNA up- or down-regulated by AGO2 shRNA.
Table S4. The miRNA up- or down-regulated by lenalidomide treatment.
(DOCX 159 kb)
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MS: Tandem mass spectrometry; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide dye; MTX: methotrexate;
My5.CRBN.His: lentiviral particles harboring human CRBN cDNA infected My5
cells; My5.LV: lentivirus vector infected My5 cells; Ni-NTA: Nickel-charged NTA
agarose beads; pCDH: pCDH-CMV-MCS-EF1; PCR: polymerase chain reaction;
qPCR: quantitative polymerase chain reaction; SDS-PAGE: sodium dodecyl
sulfate polyacrylamide gel electrophoresis; shRNA: small hairpin RNA.
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